CannabisNewsBreaks – Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Sharpens Focus on Potentially Game-Changing Sustained Release Cannabinoid Formulation

Licensed Canadian cannabis cultivation company Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) recently entered into a collaboration and licensing agreement with Canntab Therapeutics Limited to collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of Canntab’s patent-pending oral sustained release cannabinoid formulation. The agreement grants Emblem the exclusive right to Canntab’s patents and expertise in Canada to develop, commercialize, use, sell and offer—but not import or export—the product, which will be sold under the Emblem brand. An article discussing this reads: “For pharmaceutical ingredients that are typically short-acting, like cannabinoids, sustained release formulations enable dosage schedules that are more convenient, offer longer action duration and are better accepted by health care professionals and patients. The patent-pending extended release formulation being collaboratively developed by Emblem and Canntab will enable medical professionals, for the first time, to establish proper dosages for patients and will, for the patients, make it easier to take medical cannabis. Emblem believes the development of advanced dosage forms, and the pharmacokinetic and clinical research associated with this development, will effectively advance cannabinoid therapy. The company also anticipates that introducing sustained release cannabinoid formulations that are easily titratable will significantly increase the market for cannabinoid-based medications—especially for the treatment of conditions like chronic neuropathic pain.”

To view the full article, visit http://cnw.fm/UpHd1

About Emblem

Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marihuana. Emblem carries out its principal activities producing marihuana from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations. For more information, visit the company’s website at www.emblemcorp.com

More from CannabisNewsBreaks

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Leave a Reply